Here's Why InflaRx (IFRX) Is a Great 'Buy the Bottom' Stock Now
Down 20.3% in 4 Weeks, Here's Why You Should You Buy the Dip in InflaRx (IFRX)
InflaRx Announces Publication of Phase 1 Data Demonstrating Favorable Safety and Pharmacokinetic/Pharmacodynamic Profile of Izicopan
InflaRx Announces Peer-Reviewed Publication Of First-In-Human Phase 1 Clinical Data For Izicopan, Orally Administered, Next-Gen Small Molecule Inhibitor Of C5a Receptor
InflaRx Targets Kidney Protection, Steroid Reduction in AAV With Izicopan Trials
InflaRx N.V. (IFRX) Analyst/Investor Day Transcript
InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day
InflaRx N.V. (IFRX) Analyst/Investor Day - Slideshow
InflaRx Q3 EPS $(0.02) Beats $(0.07) Estimate
InflaRx Announces November Investor Events
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
InflaRx to Host Virtual Capital Markets Day
Needham Initiates Coverage On InflaRx with Buy Rating, Announces Price Target of $8
InflaRx Announces Participation in September Investor Conferences
Cantor Fitzgerald Maintains Overweight on InflaRx, Raises Price Target to $6
InflaRx (NASDAQ:IFRX) Tumbles After Q2 Results Miss Estimates
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
InflaRx Q2 EPS $(0.10) Misses $(0.08) Estimate
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.